References
- Lepore L., Pennesi M., Saletta S., Perticarari S., Pre-Sani G., Prodan M. Study of IL-2, IL-6, TNF-alpha, IFN-gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994; 12: 561–565
- Zvaifler N. J. Current concepts of pathogenesis of joint destruction in rheumatoid arthritis. Rheumatology in Europe 1995, suppl 2: 151–167
- Altomonte L., Zoli A., Mirone L., Scolieri P., Mag-Aro M. Serum levels of interleukin-lb, tumor necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 1992; 11: 202–205
- Miossec P. Pro-and antiinflammatory cytokine balance in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13(suppl 12)S13–S16
- Gordon J., Flores-Romo L., Cairns J. A., Milsum M. J., Lane P. J. CD23: a multifunctional receptor lymphokine?. Immunol Today 1989; 10(5)153–57
- Delespesse G., Sarfati M., Hofstetter H. Human IgE binding factors. Immunol Today 1989; 10(5)159–63
- Kutukculer N., Clark K., Rigg K. M., Forsythe J. L. R., Proud G., Taylor R. M. R., Shenton B. K. The value of posttransplant monitoring of interleukin (IL)-2, IL-3, 1L-4, IL-6, IL-8 and soluble CD23 in plasma of renal allograft recipients. Transplantation 1995; 59(3)333–40
- Bansal A. S., Oilier W., Marsh M. N., Pumphrey R. S., Wilson P. B. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology 1993; 79(2)285–9
- Al-Janadi M., Al-Wabel A., Raziuddin S. Soluble CD23 and IL-4 levels in autoimmune chronic active hepatitis and systemic lupus erythematosus. Clin Immunol Immunopathol 1994; 71: 33–7
- Bansal A., Roberts T., Hay E. M., Kay R., Pumphrey R. S., Wilson P. B. Soluble CD23 levels are elevated in the serum of patients with primary Sjogren's syndrome and systemic lupus erythematosus. Clin Exp Immunol 1992; 89: 452–5
- Rooney M., David J., Symons J., Di Giovine F., Var-Sani H., Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Brit J Rheumatol 1995; 34: 454–60
- Brewer E. J., Bass J. C, Baum J., et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977; 20: 195–98
- Bansal A. S., MacGregor A. J., Pumphrey R. S., Silman A. J., Oilier W. E., Wilson P. B. Increased levels of sCD23 in rheumatoid arthritis are related to disease status. Clin Exp Rheumatol 1994; 12(3)281–5
- Rezonzew R., Newkirk M. M. Impaired release of sCD23 by activated B cells from RA patients. Clin Immunol Immunopathol 1994; 71(2)156–63
- Chomarat P., Briolay J., Bancereau J., Miossec P. Increased production of soluble CD23 in rheumatoid arthritis and its regulation by interleukin-4. Arthritis Rheum 1993; 36(2)234–42
- Ikizawa K., Yanagihara Y., Kajiwara K., Koshio T., Shida T., Yamada A. Possible role of CD5+ B cells expressing CD23 in mediating the elevation of serum soluble CD23 in patients with rheumatoid arthritis. Int Arch Allergy Immunol 1993; 101(4)416–24
- Duff G. W. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol 1994; 23(suppl 100)9–19
- De Benedetti F., Robbioni P., Massa M., Viola S., Albani S., Martini A. Serum interleukin levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 1992; 10: 493–8
- Venables P. Rheumatoid arthritis and other joint diseases. Clinical Immunology 1st ed, J. Brostoff, G. K. Scadding, D. Male, I. M. Roitt. Gower Medical Publishing, Hong Kong 1991; 5.1–5.15
- Pepys M. B. Rheumatoid arthritis: The role of acute phase proteins. Brit J Rheumatol 1993; 32(suppl 3)1–2
- Spadaro A., Riccieri V., Sili Scavalli A., Sensi F., Fiore D., Taccari E., Zoppini A. Interleukin-6 and soluble interleukin-2 receptor in juvenile chronic arthritis. correlations with clinical and laboratory parameters. Rev Rhum Engl Ed 1996; 63: 171–7
- Maury C. P. Monitoring the acute phase response: comparison of tumor necrosis factor and C-reactive protein responses in inflammatory and infectious diseases. J Clin Pathol 1989; 42: 1078–82
- Ebo D., DeClerck L. S., Bridts C. H., Stevens W. J. Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjogren's syndrome. Relationship with disease activity and treatment. In-Vivo 1994; 8: 577–80